ASLAN Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016
Net Income	-44.22	-51.38	-31.59	-16.97	-47.07	-42.19	-39.89	-9.05
Depreciation & Amortization	0.35	0.33	0.28	0.3	0.45	0.24	0.21	0.08
Share-Based Compensation	2.7	1.98	2.19	0.35	0.04	1.29	1.13	1.42
Other Operating Activities	-2.15	13.11	-4.88	1.28	21.07	0.93	4.08	1.75
Operating Cash Flow	-43.32	-35.96	-34	-15.05	-25.51	-39.72	-34.48	-5.8
Capital Expenditures	-0.01	-0.03	-0.05	-0	0	-23.08	-0.3	-0.46
Change in Investments	0.28	0.44	0	0	0	0	0	0
Other Investing Activities	-	-	0.02	0	0	-0.01	-0.04	-0.07
Investing Cash Flow	0.27	0.41	-0.03	0	0.01	-23.09	-0.34	-0.52
Share Issuance / Repurchase	7.68	0	102.6	7.64	14.76	42.23	33.06	22.22
Debt Issued / Paid	-12.31	4.72	11.84	-0.24	3.01	4.06	0.23	-0.38
Other Financing Activities	15.35	-	-4.58	-0.23	1.33	-5.39	-	9.14
Financing Cash Flow	10.72	4.72	109.87	7.17	19.09	40.9	33.29	30.99
Net Cash Flow	-35.65	-33.27	75.84	-7.88	-6.71	-21.66	-1.16	24.67
Free Cash Flow	-43.33	-35.99	-34.04	-15.05	-25.51	-62.81	-34.78	-6.25
Free Cash Flow Margin	-361.09%	-	-	-	-850.21%	-	-	-54.16%
Free Cash Flow Per Share	-2.52	-2.58	-2.61	-1.96	-3.93	-10.49	-5.19	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).